verzenios
eli lilly nederland b.v. - abemaciclib - bryst neoplasms - antineoplastiske midler - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
levopidon 65 mg
dne pharma - levometadonhydroklorid - mikstur, oppløsning i endosebeholder - 65 mg
levopidon 5 mg
dne pharma - levometadonhydroklorid - mikstur, oppløsning i endosebeholder - 5 mg
levopidon 10 mg
dne pharma - levometadonhydroklorid - mikstur, oppløsning i endosebeholder - 10 mg
levopidon 15 mg
dne pharma - levometadonhydroklorid - mikstur, oppløsning i endosebeholder - 15 mg
levopidon 20 mg
dne pharma - levometadonhydroklorid - mikstur, oppløsning i endosebeholder - 20 mg
levopidon 25 mg
dne pharma - levometadonhydroklorid - mikstur, oppløsning i endosebeholder - 25 mg
levopidon 30 mg
dne pharma - levometadonhydroklorid - mikstur, oppløsning i endosebeholder - 30 mg
levopidon 35 mg
dne pharma - levometadonhydroklorid - mikstur, oppløsning i endosebeholder - 35 mg
levopidon 40 mg
dne pharma - levometadonhydroklorid - mikstur, oppløsning i endosebeholder - 40 mg